Introduction {#s1}
============

Myelin is a lipid-rich structure made by specialised glial cells, oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS), that facilitates the rapid propagation of nerve impulses and provides trophic and metabolic support to axons ([@bib59]). In mammals, myelination in the CNS starts around birth and continues well into adult life ([@bib86]). New myelin is thought to be generated by a combination of the differentiation of new oligodendrocytes ([@bib33]; [@bib35]; [@bib87]) and remodelling of existing myelin ([@bib4]; [@bib81]). New oligodendrocytes can be produced throughout life by tissue-resident oligodendrocyte progenitor cells (OPCs), which represent about 5% of CNS cells life-long ([@bib26]), and to a lesser extent by neural stem cell-derived OPCs ([@bib75]). There is increasing evidence that myelination is controlled by neuronal activity, and that regulation of myelin is important for both nervous system health and functional plasticity ([@bib2]). Indeed, loss of myelin in late adulthood correlates with age-related cognitive decline ([@bib27]; [@bib48]; [@bib65]). Reflecting its fundamental importance, it is increasingly clear that disruption to myelin and myelinating glia contributes to numerous diseases of the nervous system, including neuropathies of the PNS and a variety of conditions of the CNS. These include: neonatal hypoxia ([@bib13]); childhood leukodystrophies ([@bib8]); neurodevelopmental disorders including autism ([@bib61]) and schizophrenia ([@bib32]); as well as neurodegenerative conditions including multiple sclerosis (MS) ([@bib19]), motor neuron disease ([@bib39]), Huntington's disease ([@bib34]) and Alzheimer's disease ([@bib5]). Furthermore, disruption to oligodendrocytes and myelin play important roles in the pathogenesis of glioma ([@bib82]) and white-matter stroke ([@bib52]). However, it is now clear that OPCs and neural stem cells present in the CNS throughout life can generate new oligodendrocytes following damage to myelin, and that these cells can in turn regenerate myelin through the process of remyelination ([@bib30]; [@bib71]; [@bib75]; [@bib89]). This capacity to generate myelin throughout life, including in response to damage, raises hope that the oligodendrocyte lineage may be tractable for the treatment of disease.

Depending on the specific disease, multiple bottlenecks can limit the normal formation or regeneration of myelinating oligodendrocytes, including disruption to OPC specification, proliferation, migration, oligodendrocyte differentiation or (re)myelination, reviewed by ([@bib18]). For example, in MS, while certain areas with demyelinated axons completely lack OPCs, others have plentiful OPCs that do not differentiate into oligodendrocytes ([@bib10]; [@bib15]; [@bib45]; [@bib49]). Even when oligodendrocytes differentiate and regenerate myelin, new myelin sheaths are characterised by being shorter and thinner than normal ([@bib30]; [@bib71]). The fact that many demyelinated lesions contain OPCs that do not differentiate has prompted efforts to identify strategies to promote oligodendrocyte differentiation. Indeed, recent unbiased phenotypic screens have led to the identification of several hit compounds that promote oligodendrocyte differentiation in vitro ([@bib28]; [@bib38]; [@bib54]; [@bib55]; [@bib57]; [@bib66]; [@bib69]). A number of these hits have been validated in vivo ([@bib18]), and one, clemastine, has even shown efficacy in improving optic nerve function in patients with MS ([@bib31]). This remarkable progress highlights the power of discovery screens, and indicates that the oligodendrocyte lineage is therapeutically tractable for the treatment of disease. However, there remains a great need to identify safe, effective, and specific compounds capable of regulating distinct stages of the oligodendrocyte lineage, from specification through to (re)myelination.

In recent years zebrafish have become well established for the study of oligodendrocyte biology and myelination in vivo, reviewed in ([@bib24]). Phenotypic gene discovery screens have identified novel factors required for myelination (for example [@bib41]; [@bib50]), and live imaging based studies have provided insight into cellular mechanisms of oligodendrocyte development and myelination (for example [@bib1]; [@bib4]; [@bib22]; [@bib43]; [@bib81]). Zebrafish are now also widely used for chemical biology and drug discovery, due to their conservation of molecular and cellular function with mammals and natural properties that make them ideal for scalable and efficient compound-based in vivo screens. Zebrafish embryos can be generated in very large numbers and their externally fertilised eggs develop rapidly from a single cell to a freely swimming, optically transparent animal with extensive myelination in just a few days, meaning entire developmental events and biological processes can be observed in real time (for example [@bib42]). Compounds can be taken up by the embryo following direct addition to the water, and phenotypic screens can be carried out either by direct assessment of organ formation, cardiovascular function, general development or behaviour, or using a variety of cell-type and tissue specific markers and reporters (for example [@bib56]; [@bib60]; [@bib67] [@bib68]; [@bib74]). Since the first ground-breaking phenotypic chemical screen using zebrafish in 2000 ([@bib67]), numerous others have followed ([@bib73]), including assessment of oligodendrocyte lineage formation ([@bib12]) and a number that have led to new clinical trials ([@bib51]; [@bib60]; [@bib88]). Using an in vivo system is particularly advantageous for screening complex biological processes, such as myelination, that are difficult to fully recapitulate in vitro ([@bib11]), and recent advances in automated embryo handling technologies have made scalable in vivo screens using zebrafish feasible ([@bib16]; [@bib62]; [@bib83]). Here we combine a commercially available platform that automates the delivery of zebrafish from multi-well plates to a microscope platform, with a customised spinning disk confocal microscope to automate high-resolution image acquisition. We develop an image handling and analysis pipeline that allowed us to execute an automated screen which identified several novel hit compounds that regulate myelinating oligodendrocyte number. In addition, we expect our imaging and analysis capacities to be broadly useful to researchers interested in executing scalable, high-resolution in vivo analyses of diverse biological processes in zebrafish.

Results {#s2}
=======

Automated imaging of zebrafish larvae at high resolution {#s2-1}
--------------------------------------------------------

In order to establish an automated high-resolution in vivo screening platform for zebrafish, we decided to couple the Large Particle (LP) Sampler and the VAST BioImager ([@bib62]) (both Union Biometrica, Holliston, MA) with a customised spinning disk confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany), which together we refer to as VAST-SDCM. The LP Sampler automates the delivery of zebrafish larvae from the wells of a multi-well plate to the VAST BioImager platform ([@bib16]). Core to the VAST BioImager is a thin-walled glass capillary (10 µm thick glass) in which zebrafish can be imaged ([Figure 1A--C](#fig1){ref-type="fig"}). The capillary can be rotated fully (360 degrees) around the x-axis ([Figure 1C,D](#fig1){ref-type="fig"}; [Video 1](#video1){ref-type="video"}), such that animals can be automatically oriented according to user-defined templates ([@bib62]). We decided to use a spinning disk confocal system for image acquisition, because of the balance of high-speed and high-resolution imaging capacity with the flexibility to customise the configuration on a standard upright microscope (see Materials and methods). The VAST BioImager can accommodate glass capillaries of 600--750 µm internal diameter, which allows imaging of zebrafish embryos and young larvae ([Figure 1C,D](#fig1){ref-type="fig"}).

![VAST-SDCM setup for rapid, automated image acquisition at subcellular resolution.\
(**A**) Overview of custom VAST BioImager and spinning-disk microscope setup, highlighting key components. (**B**) Schematic representation of hardware interaction between Zeiss SDCM, VAST BioImager and LP Sampler. (**C**) Representative brightfield image produced by VAST BioImager, showing a 4 dpf zebrafish embryo in a 600 µm glass capillary. (**D**) Illustration of relative setup of microscope objective and capillary. Note that the piezo range (400 µm) requires for two stacks (blue and magenta) to be acquired per tile of fish (6-tiles with 10% overlap required to image entire 4 dpf larva). (**E**) Maximum intensity projection of images of Tg(mbp:EGFP) zebrafish, following tiled merging of 6 z-stacks. Scale bar = 200 µm. (**F**) and **G**) Example images of mid-trunk region of Tg(mbp:EGFP) and Tg(mbp:EGFP-CAAX) fish imaged with 10 × 0.5 NA (3 × 3 binning) and 20 × 1 NA (1 × 1 binning) objectives respectively. Scale bars = 50 and 25 µm respectively). dSC = dorsal spinal cord, vSC = ventral spinal cord and pLL = posterior lateral line.](elife-35136-fig1){#fig1}

###### Movie of 4 dpf zebrafish larva in the VAST BioImager capillary, showing the x-axis 360° rotational capacity.

Refers to [Figure 1](#fig1){ref-type="fig"}.

10.7554/eLife.35136.003

[Table 1](#table1){ref-type="table"} provides an overview of image acquisition parameters and performance outputs, including acquisition speeds, resolution, and general throughput of the VAST-SDCM. In initial tests using our transgenic reporter of myelinating oligodendrocytes, Tg(mbp:EGFP), we found that we could image all of the myelinating glial cells in a zebrafish larva at 4 days post fertilisation (dpf), with a success rate of 83%, in approximately 60 s, using a 10X objective (849 nm pixel size) ([Figure 1E,F](#fig1){ref-type="fig"} and [Video 2](#video2){ref-type="video"}). In addition, we imaged Tg(mbp:EGFP-CAAX) larvae, in which EGFP is membrane localised, and therefore enriched in myelin, using a 20X objective (141 nm pixel size), highlighting the potential of the system for higher resolution imaging ([Figure 1G](#fig1){ref-type="fig"}).

10.7554/eLife.35136.004

###### Imaging and Screening Statistics.

Exemplar resolution and imaging times for given pixel binning levels, using a 10 × 0.5 NA objective and imaging our Tg(mbp:EGFP) reporter line. Fish loading times by LP Sampler to VAST BioImager based on three fish per well (experiment averages 52 s for first fish and 17 s for subsequent two per well). Combined loading and imaging rates per fish for different imaging parameters.

  Pixel binning                             1 × 1   2 × 2   3 × 3
  ----------------------------------------- ------- ------- -------
  Pixel Size (nm)                           283     566     849
  Exposure (ms)                             180     45      20
  Approximate Imaging Time (s/fish)         260     80      60
  Fish loading time (s/fish)                30      30      30
  Load and Image Rate (fish/hour) 5 tiles   12      33      40
  Load and Image Rate (fish/hour) 1 tiles   43      78      85

###### Movie of maximum intensity projection of stitched confocal stacks showing a 4 dpf Tg(mbp:EGFP) animal demonstrating the ability of the VAST-SDCM system to image myelinating glia at subcellular resolution throughout the whole animal.

Images acquired at 10X, using 3 × 3 binning, pixel size 849 nm. Refers to [Figure 1](#fig1){ref-type="fig"}.

10.7554/eLife.35136.005

Given the performance obtained in our initial studies, we reasoned that the VAST-SDCM platform could provide the speed and resolution required for scalable imaging-based screens of myelinating oligodendrocyte development in vivo.

Image handling: selection of regions of interest {#s2-2}
------------------------------------------------

We first wanted to identify a region of the CNS that might be suited to an automated imaging-based screen. Myelinating oligodendrocytes differentiate in the zebrafish spinal cord from around 2 dpf, first in the ventral area and soon thereafter in the dorsal area, with significant numbers present by 4 dpf ([Figure 1E,F](#fig1){ref-type="fig"}). Due to their sparse distribution, we found that myelinating oligodendrocyte number in the dorsal spinal cord could be reliably assessed by compressing 3D z-stacks into 2D maximum intensity projections (MIPs): manual counts of cells in 2D MIPs average 33.3 vs 3D stereological counts of 35.4 (Student's t-test, p=0.61, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To develop an automated method to quantify myelinating oligodendrocyte number in this region, we first needed a method to automatically select the dorsal spinal cord as a specific region of interest (ROI) in 2D MIPs. We applied a landmark-based segmentation approach to achieve this. The early myelination of the ventral spinal cord is reflected by high-intensity fluorescent reporter expression in Tg(mbp:EGFP) animals. This allowed us to automatically plot points of peak fluorescence in the X-Y plane of tiled 2D MIPs and draw a line between points and thus delineate myelinating oligodendrocytes of the ventral spinal cord ([Figure 2A--E](#fig2){ref-type="fig"}, [Video 3](#video3){ref-type="video"}). From this defined line, we plotted the distance to the dorsal-most cells in the spinal cord, which allowed us to demarcate the dorsal spinal cord as a specific area of interest ([Figure 2F,G](#fig2){ref-type="fig"}). Our image analysis script also allows users to manually adjust any occasional errors that may occur in defining the line demarcating the ventral spinal cord (referred to as 'Refined ROIs'). However, following the fully automated ROI specification process in 196 animals, we counted on average only 1.2 cells per animal outwith the automatically assigned ROIs ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Therefore, we reasoned that we could use our 2D landmark-based segmentation process to work towards a fully automated screen to identify compounds that regulate myelinating oligodendrocyte number in the dorsal spinal cord. Whilst in this case we were able to successfully quantify our cells of interest in 2D MIPs, this is not always the case. As such, further to the above tools, we provide a method for selecting a 3D sub-region from an image dataset (3D_Crop_v1.1.ijm, see Materials and methods, [Figure 2---figure supplement 3A--C](#fig2s3){ref-type="fig"}, [Video 4](#video4){ref-type="video"}, and [@bib29]), or alternatively, a plugin for recording the depth of maximum intensity for a given xy location in a 3D dataset (D_Projector_v1.1.jar, see Materials and methods, [Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"} and [@bib29]). These allow for either removal of unwanted/non-specific fluorescence, or recording of 3D spatial information, and could be combined with the scripts presented herein.

![Fully automated ROI specification in Tg(mbp:EGFP) larval zebrafish.\
(**A**) Schematic overview of 4 dpf larvae, illustrating the region (green rectangle) of Tg(mbp:EGFP) animal imaged using VAST-SDCM (**B**). (**C**) Example fluorescence intensity profile from region demarcated by green dashed lines in B. Each point on the profile is a sum of the grey values in X for a given Y position between the green dashed lines. (**D**) Along the length of the spinal cord, each point of peak fluorescence is marked by a blue circle. The points identified in this way delineate the ventral spinal cord (**E**). This line was then used to set regions of interest for dorsal and ventral spinal cord (**F**) and higher magnification view in **G**). Scale bars B, E and F = 250 µm, D = 100 µm, and G = 50 µm.](elife-35136-fig2){#fig2}

###### Movie showing the automated process by which fluorescent intensity profiles are calculated at defined positions along the spinal cord of a 4 dpf Tg(mbp:EGFP) animal to plot the position of the ventral spinal cord.

Refers to [Figure 2](#fig2){ref-type="fig"}.

10.7554/eLife.35136.010

###### Movie showing the principle of the 3D cropping macro, starting with travelling through the z planes of a 3D dataset acquired on the VAST-SDCM of a 4dpf Tg(mbp:nls-EGFP) animal.

This is followed by a maximum intensity projection through the Z-axis, with the region to be kept highlighted in cyan. The projection is then rotated through 90 degrees, to give the Y-axis maximum intensity projection, which then has the region to be retained highlighted in cyan. The macro then removes any pixels not contained within both regions to give the final 3D dataset, which is then rotated back to the original orientation. Refers to [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}.

10.7554/eLife.35136.011

Automated quantification of oligodendrocyte cell number {#s2-3}
-------------------------------------------------------

Having established a method to automatically demarcate the dorsal spinal cord as a specific ROI, we next tested the ability of an available 2D maxima identification tool (ImageJ's inbuilt findMaxima function) to identify cells in this region. To remove false positive maxima that do not resemble cells, we included an additional processing step called processCells, which can be used to assess cell size, shape and fluorophore expression ([Figure 3](#fig3){ref-type="fig"} and see Materials and methods). These functions were applied within the automatically identified dorsal ROI, and accurately quantified cell number compared to manual assessment ([Figure 3](#fig3){ref-type="fig"} and see Materials and methods). Our image handling script also saves the selections made by the findMaxima and processCells functions for posthoc validation and further analyses. For example, in circumstances where one may wish to manually confirm accuracy of cell counts, our script also allows for manual refinement of assignments ([Figure 3](#fig3){ref-type="fig"}). Manual refinement does come with a significant cost in investigator time. For example, the completely automated process can process an individual sample in under a second and the 288 animals in a 96 well plate in 3.5 min. In contrast manual refinement takes an average of 50 s per sample to process, and circa 4 hr per plate. Nonetheless this is still significantly less time than it takes for an expert to assess cell number in the dorsal spinal cord of 288 animals from 3D stacks (circa 34 hr). In summary, the combination of automated ROI specification and automated cell counting indicated that we could, in principle, execute a fully automated image acquisition and analysis screen for compounds that regulate oligodendrocyte development using the VAST-SDCM ([Video 5](#video5){ref-type="video"}).

![Automated cell counting allows for effective quantification of oligodendrocyte cell number.\
(**A**) Crop of dorsal spinal cord of 4 dpf Tg(mbp:EGFP) zebrafish larva acquired on VAST-SDCM. (**B**) Output of ImageJ's findMaxima function (green dots), note that whilst not every cell is identified (e.g. the small dim cell indicated by orange arrow in C), some cells are identified multiple times (green arrows in C). (**C**) Output of findMaxima plus processCells function allows assessment of cell likeness, and removal of false positives, for example green arrows. (**D**) Comparison of count methods for individual fish, with ROIs and cell counts verified and corrected by a human, ROIs corrected by a human with automatic cell counts, and fully automated ROIs and cell counts.](elife-35136-fig3){#fig3}

###### Movie showing circa real-time speed of automated ventral spinal cord demarcation, dorsal spinal cord ROI selection and cell counting per animal.

Refers to [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}.

10.7554/eLife.35136.013

Validation of automated analysis to identify changes in myelinating oligodendrocyte number {#s2-4}
------------------------------------------------------------------------------------------

Following a manual screen to identify compounds that regulated myelination, using our Tg(mbp:EGFP-CAAX) reporter, we identified the compound SKP2-C25 as promoting myelination. In this manual screen we treated embryos with compounds from 2 to 4 dpf and assessed myelination at 4 dpf. Follow-up analyses showed that SKP2-C25 increased myelination, as assessed by electron microscopy, and did so by increasing oligodendrocyte number ([@bib3]). SKP2-C25 is reported to be a selective inhibitor of the Skp2 SCF ubiquitin ligase complex that contributes to the ubiquitin-directed proteasomal degradation of proteins ([@bib14]). To exemplify the power of zebrafish to define how compounds affect specific stages of oligodendrocyte lineage progression, we show here, using time-lapse microscopy that treatment of animals with SKP2-C25 increases the proliferation of OPCs between 2 and 3 dpf ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Video 6](#video6){ref-type="video"}). We have previously shown that oligodendrocytes differentiate by default in zebrafish to mediate the early myelination observed in the larval spinal cord ([@bib3]). Therefore, upon an increase of OPC proliferation following SKP2-C25 treatment, there is a larger pool of OPCs that differentiate by default, leading to the observed increase in myelinating oligodendrocytes.

###### Time-lapse movies of Tg(Olig2:GFP), Tg(sox10:mRFP) double transgenic control (top) and SKP-C25-treated (bottom) embryos imaged between 58 hpf and 70 hpf.

Refers to [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

10.7554/eLife.35136.014

Given that SKP2-C25 increased myelinating oligodendrocyte number, we decided to use this compound to assess the sensitivity of our automated imaging and analysis pipeline to detect relatively subtle changes in oligodendrocyte number. We imaged control animals and those treated with a range of concentrations of SKP2-C25 using the VAST-SDCM, and found that our imaging and analysis pipeline was indeed able to detect increases in myelinating oligodendrocyte number ([Figure 4](#fig4){ref-type="fig"}). Therefore, we reasoned that our imaging and analysis pipeline had the sensitivity to detect changes in myelinating oligodendrocyte cell number and thus could be employed to execute a fully automated screen.

![Validation of automated image analysis to identify changes in myelinating cell number induced by chemical hit.\
(**A**, **B**) Confocal images of Tg(mbp:EGFP) control (**A**) and SKP2-C25-treated (**B**) animals reflecting mean cell number per treatment (numbers refer to entire dorsal spinal cord, not magnified area of same animals). Scale bar = 100 µm. (**C**) Quantitation of cell number in control and SKP2-C25 treated animals using fully automated (grey bars) and refined counts, auto ROIs (black bars). Two-way ANOVA followed by Dunnett's multiple comparison test was used to assess statistical significance, with multiple comparison adjusted P value presented as \*p\<0.05, \*\*\*p\<0.001. Error bars represent means ± s.d.](elife-35136-fig4){#fig4}

Chemical screen for compounds that regulate myelinating oligodendrocyte number {#s2-5}
------------------------------------------------------------------------------

Having established a robust automated method for quantifying oligodendrocyte number in vivo, we next wanted to carry out a screen for regulators of myelinating oligodendrocyte formation. For this, we collated a small focused library of 175 compounds from three commercial sources (146 distinct molecular entities) that targeted enzymes implicated in epigenetic and post-translational modifications, given the known importance of epigenetic mechanisms during oligodendrocyte development ([@bib20]; [@bib47]). We reasoned that using a library with such diverse targets would allow us to identify compounds affecting distinct stages of oligodendrocyte lineage progression from OPC specification through to differentiation and myelination. To ensure that our screen would detect relatively subtle changes in oligodendrocyte number, we calculated that the sample size needed to detect the increase in cell number seen for SKP2-C25 with 95% power and p\<0.05 significance values was 9 (see Materials and methods). To account for potential automation errors (our initial data indicated an 83% success rate for accurate loading, plus subsequent positioning and imaging), the number of animals plated for analysis was increased to 12. Prior to our imaging-based screen, we first carried out an assessment of compound toxicity by treating animals from 2 to 5 dpf with all compounds at 100 µM, 10 µM and 1 µM in 96 well plate format (see Materials and methods). We found that 59/175 compounds were lethal at 100 µM, 22/175 at 10 µM, and 0/175 at 1 µM. Given that SKP2-C25 was effective in increasing oligodendrocyte number at 2 µM, and the absence of any lethal compounds in our library at 1 µM, we decided to carry out our screen of myelinating oligodendrocyte number at 2 µM.

For our screen, Tg(mbp:EGFP) embryos were dechorionated and arrayed, three per well, into 96-well plates at 1 dpf. Animals were treated with 2 µM compound at 2 dpf for 2 days (2--4 dpf), covering the developmental window in which OPCs are first specified, migrate and differentiate into oligodendrocytes that form myelin. At 4 dpf, larvae were imaged using the VAST-SDCM platform (see above and Materials and methods) and effects on myelinating oligodendrocyte number were quantified using our fully-automated processes ([Figure 5A](#fig5){ref-type="fig"} and Materials and methods). Effects of compound treatments on myelinating oligodendrocyte number were normalised against matched DMSO-treated controls for each screening session and ranked by increase in cell number ([Figure 5B](#fig5){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). Of the 146 unique compounds tested, 14 were identified as having a significant effect on oligodendrocyte number. Statistical analysis of individual experiments (from single clutches) identified five compounds as significantly increasing cell number, including the positive control SKP2-C25, and nine as decreasing, all assessed by Ordinary one-way ANOVA with Dunnett's post hoc multiple comparisons test (see Materials and methods and [Table 2](#table2){ref-type="table"}). Our positive control compound was included in two independent screening runs, but only returned as a statistically significant hit in one of those runs. Interestingly, the screening run in which it was not identified as a hit took twice as long to complete (8 vs 4 hr), reflecting the fact that variability in cell numbers will increase with time, given ongoing development of live animals. Two compounds (ML-228 and Trichostatin A) resulted in developmental lethality at the screening concentration used ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). To confirm that our fully automated image analysis was accurate and did not itself lead to the creation of false positives or negatives, we compared the results from a single screening session with manually-verified counts where the user could correct for any inaccurate spinal cord selection or oligodendrocyte quantification ([Figure 5C](#fig5){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). This comparison demonstrated that the automated and manually adjusted analyses revealed essentially identical effect sizes and identified the same hit compounds ([Figure 5C](#fig5){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}).

![Automated chemical screening pipeline in zebrafish identifies novel regulators of oligodendrocyte development.\
(**A**) Schematic of chemical screening pipeline. (**B**) Results of primary screen displayed as normalised fold change in oligodendrocyte number relative to matched DMSO-treated controls and ranked by cell increase for all 183 treatments (146 unique compounds) with hit compounds that increase or decrease cell number marked in green and toxic compounds in red. Inset shows ranking of compounds that significantly increased oligodendrocyte cell number. See also [Table 2](#table2){ref-type="table"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} (**C**) Quantification of dorsal oligodendrocyte number from a single screening session showing comparison of different analysis methods. \*p\<0.05, \*\*\*\*p\<0.0001. Error bars represent means ± s.d.](elife-35136-fig5){#fig5}

10.7554/eLife.35136.019

###### Significant Hits From Screen.

Fold change in oligodendrocyte number induced by individual hit compounds normalised to DMSO treated controls in appropriate treatment plate. For complete list of compound effects and putative targets, see [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

  Compound                 Fold change (Treated/Control)   P value
  ------------------------ ------------------------------- ---------
  Splitomicin              1.73                            0.0001
  C646                     1.73                            0.0001
  NU9056                   1.56                            0.0128
  GSK-J5 (hydrochloride)   1.41                            0.0031
  SKP2-C25                 1.31                            0.0404
  Zebularine               0.69                            0.0498
  Apicidin                 0.68                            0.0139
  Suberohydroxamic Acid    0.65                            0.0043
  IOX1                     0.56                            0.0003
  CUDC-907                 0.37                            0.009
  PI3K/HDAC Inhibitor I    0.30                            0.0006
  (+)-JQ1                  0.29                            0.0001
  JIB-04 (NSC693627)       0.08                            0.0001
  Trichostatin A           0.06                            0.0001

In agreement with previous literature on the critical role of histone deacetylation for oligodendrocyte development ([@bib21]; [@bib47]), we found several HDAC (histone deacetylase) inhibitors in our set of 9 compounds that significantly reduced oligodendrocyte cell number ([Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}, [Table 2](#table2){ref-type="table"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). The four novel compounds that significantly increased numbers of MBP-expressing oligodendrocytes in vivo (splitomicin, C646, NU9056, and GSK-J5), have activity on diverse apparent targets. Of these, splitomicin, a sirtuin histone deacetylase inhibitor ([@bib6]), and C646, a p300/CBP histone acetyltransferase inhibitor ([@bib9]), were the most effective in enhancing oligodendrocyte number, both demonstrating a 73% increase compared to controls (DMSO 41.7 ± 12.5 vs 2 μM splitomicin 72.3 ± 21.2 MBP +ve oligodendrocytes and DMSO 34.3 ± 10.1 vs 2 μM C646 59.1 ± 14.3; both p=0.0001; [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). NU9056, a selective KAT5 (Tip60) histone acetyltransferase inhibitor ([@bib17]), increased oligodendrocyte number by 56% (DMSO 38 ± 18.9 vs 2 μM NU9056 59.2 ± 12.6, p=0.013; [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). GSK-J5, which shows weak inhibition for the jumonji family of histone demethylases, ([@bib44]) increased myelinating oligodendrocyte number by 41% (DMSO 38.4 ± 9.7 vs 2 μM GSK-J5 54.2 ± 9.1, p=0.003). As our image acquisition pipeline also acquires bright-field images of each larvae, one can immediately also assess whether compounds give rise to morphological phenotypes or developmental toxicity (see examples in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

To assess the concentrations at which our four novel hit compounds functioned, and to test the possibility that we may have identified false positives, we carried out concentration series analyses of hits at 0.5, 1, 2, 4, 10 and 20 µM using the VAST-SDCM and refined ROI and refined counts analysis. All four compounds were lethal at 10 and 20 µM. NU9056 re-treatment did not demonstrate an increase in cell number at any concentration ([Figure 6](#fig6){ref-type="fig"}), suggesting the possibility that its identification in our screen represented a false positive. However, splitomicin, C646 and GSK-J5 recapitulated the observed increases in oligodendrocyte number identified in the screen ([Figure 6](#fig6){ref-type="fig"}).

![Concentration series and chemical structures of hit compounds from screen.\
For each hit identified in the primary screen, repeat treatments were carried out as before (12 fish treated from 2-4dpf), with either 1% DMSO, 0.5 µM, 1 µM, 2 µM, 4 µM, 10 µM or 20 µM of the hit treatment. For all compounds, the 10 and 20 µM treatments were fatal and are not shown on the above graphs. Chemical structures of each hit are displayed in respective graphs. One-way ANOVA followed by Dunnett's multiple comparison test was used to assess statistical significance, with multiple comparison adjusted P value presented as \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001. Error bars represent means ±s.d.](elife-35136-fig6){#fig6}

In summary, our automated screening pipeline represents an efficient, sensitive and unbiased approach for the identification of novel compounds that can promote myelinating oligodendrocyte formation.

Automated region-specific analyses to improve screening throughput {#s2-6}
------------------------------------------------------------------

To extend the functionality of our image analysis pipeline and to further characterise the effects of our hits, we wanted to assess whether the compounds identified in our screen elicited any region-specific effects on myelinating oligodendrocyte formation. Therefore, we adapted our automated image analysis script to record the x, y coordinates of each identified MBP +ve cell within the dorsal spinal cord ROI and to plot the distribution of oligodendrocytes along the anterior to posterior (A-P) axis in 100 μm bins (see Materials and methods and [Figure 7B and D](#fig7){ref-type="fig"}). This method identified a greater proportion of mbp:EGFP expressing oligodendrocytes in the anterior region of the control spinal cord, reflecting the known A-P gradient of oligodendrocyte development. As per our concentration series, we found that retreatment of animals with NU9056 at its highest tolerated dose (4 µM) failed to show a significant increase in myelinating oligodendrocyte number, when all cells in the dorsal spinal cord were assessed ([Figure 7C](#fig7){ref-type="fig"}). However, we found that NU9056 treatment caused a clear increase in oligodendrocyte number in the anterior spinal cord, but no discernible effect in the posterior spinal cord, which was also true of GSK-J5 ([Figure 7B](#fig7){ref-type="fig"}). In contrast, splitomicin, C646 and SKP2-C25 exhibited a consistent increase in cell number along the A-P axis ([Figure 7D](#fig7){ref-type="fig"}). Our region-specific assessment of hit compounds indicated that the region representing the second of five tiles along the length of the spinal cord was the most sensitive to changes in myelinating oligodendrocyte number, wherein all five compounds had significant increases in myelinating oligodendrocyte number ([Figure 7E](#fig7){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). These data suggest that analyses in single tile mode would be sufficient to detect hit compounds regulating cell number for future screens. The region-specific effects may reflect timing of the A-P gradient of oligodendrocyte lineage specification through to myelination with respect to the timing of our treatment (2 to 4 dpf), rather than a region-specific effect per se. Imaging one instead of 5-tiled z-stacks per animal would more than double the throughput of future screens, and allow us to assess myelinating oligodendrocyte number in 85 animals per hour, instead of the initial screen throughput of 40 per hour ([Table 1](#table1){ref-type="table"}).

![Automated region-specific analyses of identified hit compounds.\
(**A**) Representative single tile images of 4 dpf Tg(mbp:EGFP) larvae following treatment with the five hit compounds that increased oligodendrocyte number in our screen. Scale bar, 100 μm. Mean numbers of dorsal oligodendrocytes quantified for each treatment and in the examples shown are indicated above each corresponding image. (**B**) Plot of the anterior-posterior distribution of dorsal oligodendrocytes along the spinal cord demonstrates region-specific effects with NU9056 and GSK-J5 treatment, whereas C646, SKP2-C25 and splitomicin exhibit more consistent increases in cell number along the A-P axis (**D**). (**C**) Quantification of oligodendrocyte number throughout the entire dorsal region shows lower sensitivity for identifying compounds with region-specific effects compared with quantification within one tile region (second of five tiles) (**E**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Error bars represent means ± s.d.](elife-35136-fig7){#fig7}

Automated analysis of myelination {#s2-7}
---------------------------------

The myelin sheaths that are formed by oligodendrocytes during remyelination are abnormally short and thin ([@bib30]; [@bib71]). Therefore, the identification of compounds that promote myelination per se may be important in restoring optimal neural circuit function via myelin regeneration ([@bib18]). To develop an assay to automatically assess extent of myelination, we made use of our transgenic reporter line Tg(mbp:EGFP-CAAX), in which EGFP is targeted to the membrane of MBP-expressing oligodendrocytes ([Figure 8A](#fig8){ref-type="fig"}; \[[@bib1]\]). To quantify changes in myelination, we first applied our landmark-based segmentation approach to select the dorsal region of the spinal cord, as above for Tg(mbp:EGFP). After ROI selection, we used ImageJ's 'getRawStatistics' function to quantify the average fluorescence intensity throughout the segmented region, as a proxy for the extent of myelination (see Materials and methods). We first tested whether this assay could identify the known increase in myelination over time and indeed found significant increases in mean fluorescence intensity in the dorsal spinal cord of our Tg(mbp:EGFP-CAAX) from 3-4 dpf and 4--5 dpf, respectively (average dorsal grey values -- 1 × 1 binning, 80 ms exposure, 3 dpf: 4.91 ± 0.68; 4dpf: 19.1 ± 6.41, p\<0.0001 (3 vs 4 dpf); 5 dpf: 33.28 ± 11.44, p\<0.0001 (4 vs 5 dpf); [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). We next wanted to investigate if our hit compound splitomicin exhibited an increase in myelination, according to this assay. Automated quantification of splitomicin-treated larvae revealed a significant increase in mean dorsal fluorescence intensity over multiple concentrations compared with control-treated larvae, despite this being difficult to subjectively appreciate by eye (average dorsal grey values -- 3 × 3 binning 60 ms exposure, DMSO 136.1 ± 35.9 vs 2 μM splitomicin 174.7 ± 34.3, p=0.0023; 3 μM splitomicin 186.4 ± 33.3, p=0.0001; 4 μM splitomicin 203.4 ± 38.3, p=0.0001 [Figure 8B](#fig8){ref-type="fig"}). To confirm that this increase in fluorescence did indeed reflect a change in bona fide myelination, we performed transmission electron microscopy on 4 dpf larvae and found a \~1.8 fold increase in myelinated axon number in splitomicin-treated animals (DMSO 9.8 ± 4.3 vs 2 μM splitomicin 18 ± 2.6, p=0.0065; [Figure 8C--E](#fig8){ref-type="fig"}). Therefore, our fluorescence intensity-based assay provides an unbiased, automated approach for the quantification of myelination in vivo, with higher sensitivity than subjective manual assessment. Future screens will be carried out to identify compounds that can promote myelination in and of itself.

![Treatment with splitomicin increases spinal cord myelination in vivo.\
(**A**) Representative images of myelin within the spinal cord of control (top) and splitomicin-treated (bottom) Tg(mbp:EGFP-CAAX) larvae. Scale bar, 50 μm (**B**) Quantification of mean fluorescence intensity throughout the entire dorsal spinal cord demonstrates a significant increase following 2--4 μM splitomicin treatment from 2-4 dpf. (**C**) Schematic of a transverse section through the zebrafish spinal cord shows the position of myelinated axons (blue) in relation to the gray matter (neuronal cell bodies are coloured in grey). Red box indicates approximate area shown in (**D**) in which myelinated axon number was quantified. (**D**): Transmission electron micrographs of control (left) and splitomicin-treated (right) larvae at 4 dpf with myelinated axons pseudo-coloured in blue. Scale bar, 1 μm (**E**) Numbers of myelinated axons in the dorsal spinal cord are significantly increased following 2--4 dpf treatment with 2 μM splitomicin. \*\*p\<0.01, \*\*\*\*p\<0.0001. Error bars represent means ± s.d.](elife-35136-fig8){#fig8}

Finally, to test whether compound function in zebrafish was conserved in mammals, we tested whether treatment of rat primary oligodendrocytes with splitomicin also affected the mammalian oligodendrocyte lineage. Indeed, we found that two-day treatment of cultures immediately following plate-down (see Materials and methods) resulted in a robust increase in the number of MBP expressing oligodendrocytes ([Figure 9](#fig9){ref-type="fig"}). Furthermore, we assessed proliferation (using an antibody recognising Ki67) of oligodendrocyte lineage cells (using an antibody recognising olig2). We saw an increase in the number of Ki67-expressing, olig2-expressing cells, upon splitomicin treatment ([Figure 9](#fig9){ref-type="fig"}), indicating that the observed increase in myelinating oligodendrocyte number was due to increased proliferation and subsequent differentiation of a larger pool of OPCs. Therefore, our identification of splitomicin as a regulator of the oligodendrocyte lineage in zebrafish was validated as having the capacity to regulate the mammalian oligodendrocyte lineage. Future studies will investigate the conservation of function of our other hits in the mammalian oligodendrocyte lineage.

![Splitomicin enhances mammalian oligodendrocyte generation in vitro.\
(**A**) Representative images of rat oligodendrocyte cultures treated with 1% DMSO or 3 µM splitomicin, stained for antibodies that recognise MBP, Olig2 and Ki67. Scale bar = 50 µm. (**B**--**D**) Quantification of Olig2+ cell number (B), MBP+ cell number (**C**) and Ki67+ Olig2+ cell number (**D**). Shapiro-Wilk normality test determined that datasets were not normally distributed. Therefore, a Kruskal-Wallis test was followed by Dunn's multiple comparison test to test statistical significance between conditions. \*p\<0.05, \*\*p\<0.01. Error bars represent means ± s.e.m.](elife-35136-fig9){#fig9}

Discussion {#s3}
==========

Here we describe the development of a fully automated, sub-cellular resolution, in vivo chemical screening pipeline, which we have used to identify compounds that promote myelinating oligodendrocyte formation in zebrafish. By combining the now commercially available LP Sampler and VAST-BioImager (both Union Biometrica) with a spinning disk confocal microscope (VAST-SDCM), we automated the delivery, orientation, and high-speed, sub-cellular resolution imaging of zebrafish. We developed an image handling and analysis pipeline that automates file handling tasks, and which also allows assay-specific operations including region of interest selection and a variety of quantitative assessments, such as analyses of cell number, distribution, shape and fluorescence intensity. We have implemented and exemplify the power of this pipeline to identify compounds that regulate myelinating oligodendrocyte lineage formation. Importantly, our imaging platform and image analysis scripts can in principle be adapted to execute a variety of assays relevant to numerous biological processes of interest to the community. Our custom scripts are freely available at <https://github.com/jasonjearly/VAST-SDCM> ([@bib29]; copy archived at <https://github.com/elifesciences-publications/VAST-SDCM>).

Scaling up and refining high-resolution quantitative in vivo screens {#s3-1}
--------------------------------------------------------------------

Here we demonstrate the power of the VAST-SDCM platform and automated image handling and analysis scripts by carrying out a small screen of compounds, which were tested for their ability to promote oligodendrocyte lineage progression. We identified three novel compounds that reproducibly increased myelinating oligodendrocyte number (C646, GSK-J5 and splitomicin). However, each of these compounds, and our positive control compound, SKP2-C25, functioned over a relatively tight concentration range, and exhibited somewhat variable effects. Indeed, SKP2-C25 only served its function as a positive control one out of the two times that it was tested in the screen, and C646 only exhibited statistically significant increases in oligodendrocyte number in one of the three times it was screened, although it did have trend increases of similar effect size all three times (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). Interestingly, the durations of screening runs in which these compounds were not returned as hits were longer than those from which they were, reflecting the fact that variability in cell number will increase over time, given that continuously developing live animals are being examined. The false negatives may also be due to the narrow concentration windows of efficacy ([Figures 4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}), coupled with the fact that researchers typically don't assess actual compound concentration prior to a screen. These examples serve to highlight the issue of false negatives that need to be addressed with any chemical screening platform. To reduce variability due to protracted screening runs, we recommend screening individual compounds over shorter periods of time, when using live animals, by adjusting their distribution across screening plates accordingly. In addition, to mitigate false negatives due to restricted windows of efficacy, one could carry out high-resolution screens at multiple concentrations within doses well tolerated by the animal. This would clearly require the processing of more animals per screen and represent a trade-off between increased throughput and reduced error rate. We have demonstrated that for our oligodendrocyte cell number assay, imaging and screening a single tile instead of the entire animal would have been as effective in hit identification, and more than halved the screening time. This would have allowed us to assess about 85 animals per hour, instead of 40. To further scale up screening capacity on this platform, another option may involve pooling distinct compounds, and assessing the ability of pools to elicit phenotypes. One could then subsequently identify the effective compound(s) in the active pool(s). The pooling of compounds is most likely to be effective for compounds with limited toxicity and thus will differ library to library. However, this may be an effective way in which to greatly scale up the utility of the VAST-SDCM system.

To best ensure reliability of screens and to reduce error rates in so far as possible, the use of positive controls and appropriate powering of experiments is essential. We would advise investigators initiating quantitative screens that aim to identify subtle phenotypes to run robust positive controls throughout individual screening runs where possible. Prior to the initiation of our screen, our power calculations indicated that a reduced n = 6 would have had a power of 80% to detect changes in cell number of 35% (vs 95% for n = 9, which we scaled to 12 to account for occasional failure to image samples correctly). Indeed, the success rate of fish loading through to automated data analysis was 80% across the entire screen, meaning that on average our actual n was just over nine per condition. Following our screen, we analysed our raw data and assessed what hits we would have identified, if we compared our actual n for each hit compound compared to n = 6 or n = 3 ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). Interestingly, at an n = 6 only C646 and SKP2-C25 would have been identified as hits, and the absence of identifying the validated hits splitomicin and GSK-J5 would have represented false negatives. In addition, at the lower n values, we would have identified one false positive hit at n = 6 and two at n = 3 ([Supplementary file 4](#supp4){ref-type="supplementary-material"}), and incurred six false negatives at n = 6 and 12 at n = 3 ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

Our desire to test the ability of the system to identify hits that regulated cell number by 35% was stringent. If a larger effect size threshold was used, then a lower 'n' would suffice. For example, if we defined a criterion for a hit as having the ability to change myelinating cell number by \>75% with 95% power, then in principle an n of 3 would suffice. Therefore, in the design of any quantitative screen, one needs to consider the definition of what constitutes a hit and to power the analysis based on known variability in the parameter being assessed accordingly.

Novel regulators of oligodendrocyte formation {#s3-2}
---------------------------------------------

Following our screen, we identified and validated four compounds that promote myelinating oligodendrocyte formation in larval zebrafish. Splitomicin is a small molecule inhibitor of the sirtuin family of NAD^+^-dependent HDACs ([@bib6]), with reported activity for sirtuin 1 and 2 (sirt1 and sirt2) in mammalian cells in vitro ([@bib63]). Sirt1 shows broad protein expression throughout the rodent CNS ([@bib80]), but has been implicated in regulating the oligodendrocyte lineage. For example, conditional genetic inactivation of sirt1 in adult rodent neural stem cells led to an increase in OPC formation, and a consequent increase in remyelination following toxin-induced demyelination ([@bib72]). Interestingly, the opposite effect on the oligodendrocyte lineage has been reported in neonatal animals, with reduced numbers of proliferating OPCs following sirt1 knockdown and increased oligodendrocyte differentiation under hypoxic conditions suggesting a context-dependent role for sirt1 ([@bib36]). In contrast to sirt1, sirt2 expression is highly enriched in the oligodendrocyte lineage, and is upregulated in newly differentiating and myelinating oligodendrocytes ([@bib84]; [@bib91]). However, despite its specific expression in the oligodendrocyte lineage, the role of sirt2 in regulating oligodendrocyte differentiation and myelination remains somewhat unclear ([@bib37]; [@bib46]). Our data suggest that splitomicin increases myelinating oligodendrocyte number in both zebrafish and rat, but it remains unclear whether these effects are mediated via sirt1 and/or sirt2 or indeed on another unknown target. Therefore, the validation of targets engaged by hit compounds, by genetic and biochemical means, is essential to disentangling the mechanistic basis of compound function. In addition, future genetic investigation of the role of prospective targets in a cell-type specific manner will be required to explore their relative roles in the oligodendrocyte lineage and in other cell types. Although we did not see general effects on animal development with our hit compounds, we cannot rule out roles in other cells, particularly as these regulators are broadly expressed. Our second ranked hit, C646, is a competitive inhibitor of the CBP/p300 family of histone acetyltransferases (HATs) ([@bib9]). As transcriptional co-activators, CBP and p300 have been implicated in coordinating cell fate decisions through their interactions with numerous histone and non-histone related proteins in vitro ([@bib58]; [@bib90]). Notably, CBP can acetylate the transcription factor olig1 and regulate its nuclear to cytoplasmic localisation, which is associated with oligodendrocyte differentiation ([@bib25]), and p300 levels have been shown to be altered in a subset of patients with MS ([@bib64]). The third novel hit that was validated in all subsequent assays, GSK-J5, displays weak activity for the jumonji (JMJ) family of histone demethylases in mammalian in vitro assays and for this reason is recommended as a structure-matched inactive control for the more active isomer, GSK-J4 ([@bib44]). This fact, coupled with the finding that GSK-J4 and other selective JMJ inhibitors within the library had no effect on oligodendrocyte number in our screen, suggests that GSK-J5 may promote myelinating oligodendrocyte formation through an alternative target, again highlighting the issue of target validation ([@bib76]). From the point of view of both hit and target validation, it is important to note the value of using multiple compounds (ideally structurally diverse) that are purported to hit the same target. Given that most compounds are likely to bind to more than one target in vivo, if several compounds with an overlapping target elicit the same phenotype, then one has a better foundation upon which to pursue the more challenging genetic and biochemical methods of target validation.

Our pilot screen identified hits that robustly increase myelinating oligodendrocyte number. However, extensive further studies will be required to fully characterise the mechanisms by which these compounds affect specific stages of the oligodendrocyte lineage. The ability to carry out time-lapse imaging of oligodendrocyte lineage progression in vivo using zebrafish offers a great advantage in assessing when compounds mediate their functions, as shown for SKP2-C25 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Video 6](#video6){ref-type="video"}). Future time-lapse studies will explore how our other hit compounds affect the dynamic development of the oligodendrocyte lineage in vivo. In addition, the development of further stage-specific reporters and markers in zebrafish coupled with complementary studies in cell based platforms allow further dissection of the timing and cellular mechanisms of compound activities.

Versatility and future potential of the VAST-SDCM platform {#s3-3}
----------------------------------------------------------

We exemplify the potential of the VAST-SDCM system for discovery screens using a transgenic reporter of myelinating oligodendrocytes, and myelination, but essentially any reporter of interest can be imaged using this platform. The system has multiple excitation laser lines and two cameras that allow simultaneous imaging in two channels without any increase in imaging time, meaning that two assays could be screened in parallel, given appropriate reporters, or several reporters in parallel with some increase in imaging times. In addition, the platform can accommodate photo-ablation and photo-activation lasers for acute manipulations, and the stability of larvae in the imaging capillary, and speed of the SDCM imaging system is such that up to minutes long time-lapse microscopy could, in principle, be carried out on individual animals. A recent update to the liquid handling system now means that the platform can be configured such that zebrafish can be dispensed back in to the wells of multi-well plates from the BioImager, allowing for collection of embryos for further study, for example genotyping or re-imaging.

In addition to the obvious versatility of the imaging platform, we have also extended our image analysis scripts to provide additional functionalities. One common issue when dealing with fluorescently labelled reporters or markers is expression in tissues outwith areas of interest, or disruptive auto-fluorescence, for example in the zebrafish skin. To exemplify this utility, we segmented the spinal cord from its surrounding peripheral tissue in Tg(mbp:nls-EGFP) animals, which also express nuclear-localised EGFP in peripheral Schwann cells ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Video 4](#video4){ref-type="video"}, and see Materials and methods). In principle, our landmark-based segmentation approach can be implemented in a case by case reporter-dependent manner for selection of 3D ROIs. However, in situations where there are no opportunities to assign a reference landmark, one could assign ROIs by determining average distances from the reference landmark in our transgenic reporters. We executed our screen using 2D images, because we found that cell number could be as accurately assessed from 2D MIPs as 3D z-stacks. However, in some cases information on the 3D nature of manipulations will be of importance. Therefore, we added another optional functionality to our image analysis pipeline, which allowed us to encode quantitative information relating to individual images in a z-stack in 2D MIP images ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} and see Materials and methods). This approach has the benefit of allowing one to assess effects of experimental manipulations in 3D without the storage and processing issues associated with dealing with high-content 3D imaging datasets. In general, it is desirable in a screen to maximise data use and minimise costs (monetary and time) associated with storage and processing of very large datasets.

In addition to serving as a powerful discovery system, zebrafish present numerous advantages for the deep phenotypic characterisation of compound function on biological processes. In particular, their suitability for live imaging and the myriad transgenic reporters of various molecules, cells and tissues, allow the effects of compounds on cell behaviours to be followed with high spatial and temporal resolution in the living animal in ways that are hard to achieve in other vertebrates ([@bib7]). Furthermore, the ability to directly observe tissue development and health at scale and over time-scales of days, presents remarkable advantages for drug development projects that need to triage chemical structures with possible deleterious effects. In addition to serving as a platform for phenotypic discovery screens, the VAST-SDCM is also suited to more focussed target-driven studies, for example the profiling of arrays of compounds designed to hit individual targets. Coupled with the capacity to image essentially any molecule, cell, or tissue type with a sufficiently robust fluorescent reporter, the VAST-SDCM platform provides a versatile option for scalable (medium--throughput) high-resolution focussed approaches. Automated higher-throughput, lower resolution in vivo screening capacities have recently also been demonstrated using zebrafish ([@bib83]). The availability of screening options at multiple scales highlights the power of zebrafish as a discovery model. We expect that our implementation of VAST-SDCM and our adaptable image handling and analysis scripts will be of value to the wider research community, and we invite interested users to contact us.

Materials and methods {#s4}
=====================

Zebrafish husbandry and transgenic lines {#s4-1}
----------------------------------------

Adult zebrafish were housed and maintained in accordance with standard procedures in the Queen's Medical Research Institute zebrafish facility. All experiments were performed in compliance with the UK Home Office, according to its regulations under project licenses 60/4035 and 70/8436. Adult zebrafish were subject to a 14/10 hr, light/dark cycle. Embryos were produced by pairwise matings and raised at 28.5°C in 10 mM HEPES-buffered E3 Embryo medium or conditioned aquarium water with methylene blue. Embryos were staged according to hours or days post-fertilisation (hpf or dpf). The following transgenic lines were used for this study: Tg(mbp:EGFP) ([@bib1]), Tg(mbp:EGFP-CAAX) ([@bib1]), Tg(mbp:nls-EGFP) ([@bib40]), Tg(olig2:EGFP) ([@bib79]) and Tg(sox10:mRFP) ([@bib43]).

Hardware setup (VAST-SDCM platform) {#s4-2}
-----------------------------------

We used the Large Particle (LP) Sampler and VAST BioImager (Union Biometrica) to automate the delivery of zebrafish from the wells of multi-well plates to the BioImager microscope platform. To combine the power of the VAST BioImager platform to automatically orient zebrafish within a thin-walled glass capillary according to user-defined templates with high-speed imaging, we mounted the BioImager platform on an upright Axio Examiner D1 (Carl Zeiss) microscope, fitted with a high-speed CSU-X1 spinning disk confocal scanner (Yokogawa, Tokyo, Japan). All animals were imaged from a lateral view. In order to optimise the field of view, we added a 1.6X post-magnification adaptor to the light path, which when combined with a C-Plan-Apochromat 10X (0.5NA) dipping lens (Carl Zeiss) and dual AxioCam 506 m CCD cameras (Carl Zeiss), allowed acquisition of images with X-Y dimensions of 662 µm x 492 µm, such that the majority of the capillary's 600 µm Y-axis could be captured. The imaging system was configured with 50 mW 405 nm, 50 mW 488 nm and 20 mW 561 nm lasers and two AxioCam 506 m CCD cameras, high-speed emission filter wheel with 450/50, 520/35 and 527/54 + 645/60 nm emission filters for camera 1, and a fixed 630/98 nm emission filter for simultaneous acquisition.

To ensure rapid image acquisition in the z-plane, we employed a long-range, high-speed PIFOC P-725.4CD piezo objective scanner (Physik Instrumente, Karlsruhe, Germany), capable of up to 400 µm high speed travel.

The VAST BioImager microscope platform can be moved in the x, but not y-axis. To generate stitched z-stacks the system needs to hand control back and forth (via Transistor-Transistor Logic, TTL, commands, [Figure 1](#fig1){ref-type="fig"}) between the VAST BioImager software (Union Biometrica) and the microscope's image acquisition software, Zen Blue 2.0 (Carl Zeiss). This allows interspersed rounds of acquisition of individual z-stacks and movement of the BioImager platform in the x-axis ([Figure 1](#fig1){ref-type="fig"}). For higher resolution imaging, a C-Plan Apochromat 20X (1NA) dipping lens (Carl Zeiss) was employed.

Custom software {#s4-3}
---------------

All custom software and scripts used in this work are freely available at <https://github.com/jasonjearly/VAST-SDCM> ([@bib29]).

Automation of file handling {#s4-4}
---------------------------

All file handling was automated using custom ImageJ Macro Language (IJM) scripts ([@bib77]; [@bib78]). Due to the nature of the communication between the VAST BioImager and microscope (a simple TTL signal), the images acquired by the microscope contain no fish or well-specific information. To overcome this issue, our image processing scripts include functions to cross reference image acquisition times with the VAST BioImager signal times (recorded by VAST in a .csv file) for specific tile locations for individual fish for each well sampled. This data was then used to concatenate upper and lower z-stacks, stitch tiles of z-stacks, generate maximum intensity projections of tiled z-stacks, and finally to perform cell counts. File stitching was carried out using FIJI's inbuilt Grid/Collection Stitching plugin ([@bib70]). Additional quality control checks were applied to the output of the stitching plugin to ensure that stitched image dimensions fell within a given tolerance of those expected. Any images outwith these dimensions are highlighted to the user. This file management process is carried out by the Process_VAST_v1.1.ijm macro ([@bib29]).

Automation of ROI selection {#s4-5}
---------------------------

ROI selection was performed using the plotROI function of our custom image analysis script, CountCells_2D_v1.1.ijm ([@bib29]). This function first identifies the ventral spinal cord of the Tg(mbp:EGFP) transgenic zebrafish line by repeated sampling of 150 µm blocks of the image along the x-axis, with the sum of grey values for each y-position within a block used to identify the peak fluorescence in y for the block (see [Figure 2](#fig2){ref-type="fig"}). This process was carried out using the getProfile function of ImageJ for a line of width 150 µm. The stereotyped nature of the fluorescence in this transgenic line means that the identified peaks delineates the ventral spinal cord of the embryo. Due to the sparse distribution of cells in the posterior spinal cord, an additional step was added to find the final cell. A best fit straight line was produced from the last four successful ventral spinal cord points and extrapolated caudally. This line was sampled to identify the last potential cell falling within 20 µm, above or below this best fit ([Figure 2](#fig2){ref-type="fig"}).

Using the line representing the ventral spinal cord of the fish, regions of interest were then set for the dorsal and ventral spinal cord, as well as the entire structure. Polygon regions are created with characteristic dimensions. In addition, in order to mimic the narrowing of the spinal cord, the dorsal region was tapered linearly towards half its original height, at the posterior ([Figure 2](#fig2){ref-type="fig"}). All regions of interest were then saved for subsequent inspection or repeated measurements.

Whilst this method has been used to segment the dorsal spinal cord using the Tg(mbp:EGFP) reporter, the principle of this technique could be broadly applied to other structures of interest.

Automated cell counting {#s4-6}
-----------------------

Cell counts were carried out using the CountCells_2D_v1.1.ijm macro ([@bib29]). Cell counting was first performed within the regions identified by the plotROI function, using ImageJ's findMaxima function. The findMaxima function requires an input threshold which sets the minimum difference in fluorescence between two potential maxima to allow them to be identified as distinct peaks (i.e. the minimum drop in fluorescence between two peaks).

Whilst initial tests showed that the findMaxima function was able to identify differences between positive and negative control treatments, at lower input threshold values, many false positive points were produced (data not shown). At these lower thresholds, brighter cells possess multiple maxima, due to lack of fluorescence homogeneity (green arrows in [Figure 3](#fig3){ref-type="fig"}), while at even lower thresholds, background noise may be identified as a cell.

To prevent over assignment of false positive hits using the findMaxima function, the processCells function was developed to refine the raw findMaxima point selection. For each point identified by the findMaxima function, ImageJ's doWand function was used to select connected pixels (with a tolerance of half that point's peak intensity). Statistics were then produced for the putative cell using the getStatistics and ROI.getBounds functions of ImageJ. The size and shape of the produced selection were then assessed for cell likeness, and false positives removed. Additional cell likeness criteria (such as minimum, maximum or standard deviation of fluorescence intensity) can readily be applied by minor modification to the processCells function. Maxima which did not fit the cell likeness criteria were discarded, and refined point as well as polygon outline selections were saved for further analysis (see binned cell counts method, below). Appropriate thresholds were identified for a given dataset using the intelligentThresh function. This function takes user adjusted cell counts from five randomly selected fish and identifies the threshold which gave the closest match to the human cell count.

Binned cell counts {#s4-7}
------------------

The relative distribution of cells along the length of the spinal cord was automatically determined using a custom ImageJ script (see script Plot_Distribution_v1.1.ijm, [@bib29]). This script takes the point selection and the ventral spinal cord selection produced by the cell counting script, for each fish, and assigns an x-coordinate to each point. This x-coordinate was calculated by identifying the closest point on the ventral spinal cord to each cell. This calculation was necessary to account for the variable curvature of the spinal cord as well as any minor fish positioning errors. Cell numbers were then binned based on these calculated x-positions.

Tg(mbp:EGFP-CAAX) intensity measurements {#s4-8}
----------------------------------------

Relative quantities of myelin were estimated between treatments using ImageJ's 'getRawStatistics' function, which measured the mean grey value within the whole zebrafish spinal cord, as selected by the plotROI function, with manual user adjustment of the ventral spinal cord selection to ensure an accurate selection. The measurement was performed on stitched maximum intensity z-projections for each fish, using an adapted version of the CountCells_2D macro, see CAAX_Analysis_v1.1.ijm ([@bib29]).

3D volume segmentation {#s4-9}
----------------------

A custom ImageJ script (see script 3D_Crop_v1.1.ijm, [@bib29]) was written to present a user with orthogonal maximum intensity projections of a z-stack, to which selections may be made and added to ImageJ's ROI manager. The script identifies ROIs wholly contained within the xy, xz or yz regions, and sets all pixels outside these regions to 0 for all slices, in their respective view. This creates an AND effect, where only pixels included in all ROIs are retained. The script outputs a new z-stack with the retained pixels and, optionally, the discarded pixels.

Depth projection {#s4-10}
----------------

To efficiently map the depth of maximum intensity for each pixel in xy of acquired z-stacks, the inbuilt ImageJ ZProjector plugin was adapted (see D_Projector_v1.1.jar, [@bib29]) to record this information in a secondary 2D image (termed the depth projection, or dProj). This secondary dProj image was then masked with the cell profiles created by the processCells function, and any non-cell pixel set to 0 for the purposes of illustration ([Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). A lookup table was applied to the subsequent image to illustrate the additional contrast possible with this method.

Sample size calculation {#s4-11}
-----------------------

A sample size calculation was performed using the method described recently by ([@bib85]). The following equation was used to calculate the required sample size (n), based on a sample data set of DMSO treated and positive control treated animals (data not shown).$$n = \frac{2\sigma^{2}\left( {Z_{\beta} + \frac{Z_{\alpha}}{2}} \right)^{2}}{\left( {\mu_{\rho} - \mu_{\eta}} \right)^{2}} \times 1.15$$

Where σ, Z~β~, Z~α~, μ~ρ~ and μ~η~ are standard deviation (of control with largest variance), required power, required level of statistical significance, mean of positive control group and the mean of negative control group respectively.

Chemical screen: larvae preparation and compound treatments {#s4-12}
-----------------------------------------------------------

Out-crosses of the Tg(mbp:EGFP) transgenic line were used for the primary screen. At 24 hpf, embryos were enzymatically dechorionated using protease from Streptomyces griseus (0.5 mg/mL for 6 min) (Sigma-Aldrich, St. Louis, MO) and manually arrayed into 96-well plates in a volume of 225 μL E3 media (three embryos per well). At 48 hpf, larvae were checked for viability, and any unhealthy animals were manually removed and replaced in equal volumes with clutch-matched larvae. 10 mM compound stocks in DMSO (Xcess Biosciences, San Diego, CA; SelleckChem, Houston, TX; CaymanChem, Ann Arbor, MI) were serially diluted using a multi-channel pipette to a 4X concentrated treatment solution. Between 48--51 hpf, 75 µL of this 4X stock was added directly into the larval wells for a final concentration of 2 μM in 1% DMSO. Each compound was tested on 4 wells of 3 fish per well (n = 12) and compared against 1% DMSO negative controls within the same plate. Treatment plates were then kept within secondary chambers to reduce evaporation and incubated under standard temperature conditions for 2 days without compound refreshment. At four dpf, larvae were anaesthetised with 600 µM tricaine prior to imaging. For the preliminary qualitative screen, embryos were manually mounted in 1.1% low-melting agarose (Invitrogen) on a glass coverslip, and suspended over a microscope slide using high vacuum silicone grease to create a well containing embryo medium and 600 µM tricaine.

Treatments were imaged such that replicate wells were imaged throughout the day (i.e. Treatment 1 well 1, Treatment 2 well 1, Treatment 3 well 1..., Control well 1, **then** Treatment 1 well 2, Treatment 2 well 2, Treatment 3 well 2..., Control well 2...), to spread any variability due to development whilst imaging live animals over time.

Time-lapse imaging {#s4-13}
------------------

For time-lapse imaging Tg(sox10:mRFP; olig2:GFP) larvae were used. Zebrafish larvae were treated at 48 hpf with SKP2-C25 (1% DMSO). At 56--57 hpf, larvae were anaesthetised in 600 μM tricaine and manually mounted in 1.5% low melting point agarose in embryo medium containing either SKP2-C25 (1% DMSO) or 1% DMSO and 600 μM tricaine. Time-lapse imaging was performed using a Zeiss LSM710 confocal microscope (Carl Zeiss) with a temperature controlled stage set to 28.5°C throughout imaging. Images of the middle region of the spinal cord (somite 15 = centre of image) were acquired using a 20X objective (Zeiss Plan-Apochromat 20X dry, NA = 0.8), zoom 1, corresponding to a 425 μm region of the spinal cord. Dual colour Z-stacks (488 and 594 nm lasers) were acquired every 14 min over 16 hr of the full depth of the spinal cord with 2 μm Z-interval. Larvae were checked the following morning for viability and general health with any unhealthy animals excluded from analysis. For analysis, maximum-intensity projections were made for each time point over the 16 hr imaging period. To reduce x-y drift, dual-colour images were registered using the olig2:EGFP channel and 'Register virtual stack slices' plugin in Fiji. The 'Transform virtual stack slices' plugin was then used to apply the same transformations to the sox10:mRFP channel. Dorsal OPC migration and proliferation events were manually quantified over a 12 hr period from 58 to 70 hpf using the Cell Counter plugin in Fiji.

In vitro OPC differentiation assay {#s4-14}
----------------------------------

Cortical mixed glial cultures were generated from Sprague Dawley rats P0-2, as described previously ([@bib53]). After 10--12 days of expansion oligodendrocyte progenitor cells were mechanically separated, counted and grown on poly-D-lysine coated 18 mm coverslips at a density of 75,000 cells per well. Cells were grown in myelination media: 50:50 DMEM:Neurobasal Media, B27 supplement, 5 µg/mL N-acetyl cysteine, and 10 ng/mL D-biotin, ITS and modified Sato (100 µg/mL BSA fraction V, 60 ng/ml Progesterone, 16 µg/ml Putrecsine, 400 ng/mL Tri-iodothyroxine, 400 ng/mL L-Thyroxine), at 37°C in 7.5% CO2. Treatments were added at plating and refreshed after 24 hr.

Cells were fixed after 48 hr with 4% PFA for 15 min and blocked for 30 min in 10% goat serum and 0.1% triton-X-100 at room temperature. Primary antibodies were diluted in blocking solution and applied overnight at 4°C: mouse anti-Olig2 (1:200, Millipore; MABN50), rat anti-MBP (1:250; AbD Serotec; MCA409S) and rabbit anti-Ki67 (1:250; Abcam; ab16667). Cells were incubated with fluorescently conjugated secondary antibodies diluted in blocking solution (1:1000, Life Technologies-Molecular Probes), for 1 hr at room temperature and counterstained with Hoechst (5 µg/ml). Five random images were taken per coverslip on a Leica SP8 confocal microscope (20X objective) and counted using ImageJ, double blind to condition. A Shapiro-Wilk normality test was used to determine normality of distribution. Because data were not normally distributed, a Kruskal-Wallis test was followed by Dunn's multiple comparison test to test statistical significance between conditions. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Error bars represent means ± s.e.m.

Transmission electron microscopy {#s4-15}
--------------------------------

Tissue was processed for electron microscopy as previously described ([@bib23]). Briefly, 4 dpf larvae were anaesthetised with tricaine and chemically fixed with microwave stimulation using a solution of 2% glutaraldehyde, 4% paraformaldehyde in 0.1 M sodium cacodylate buffer (Agar Scientific, Essex, UK). Embryos subsequently underwent secondary fixation with microwave stimulation in 2% osmium tetroxide in 0.1 M sodium cacodylate/imidazole (Agar Scientific) followed by en bloc stain in saturated uranyl acetate (\~8%, w/v, in water) (TAAB Laboratories Equipment Ltd., Berkshire, UK). Samples were then progressively dehydrated in a series of ethanol and acetone washes before being embedded in Embed-812 resin (Electron Microscopy Sciences, Hatfield, PA). Ultra-thin sections (70 nm thickness) were cut around somite 15 using a Reichert Jung Ultracut microtome (Leica Microsystems, Wetzlar, Germany) and stained using uranyl acetate (TAAB Laboratories Equipment Ltd.) and Sato lead stain (see ([@bib23]) for detailed protocol). Stained sections were imaged using a Jeol JEM-1400 Plus transmission electron microscope (JEOL USA, Inc., Peabody, MA) at 8600x magnification. Individual tiles were automatically aligned using the PhotoMerge tool in Adobe Photoshop CC (Adobe Systems Inc., San Jose, CA) and quantified manually using Fiji (ImageJ).

Statistical analyses {#s4-16}
--------------------

All data are expressed as mean ± SD, unless otherwise stated. Statistical tests were carried out using GraphPad Prism 7. All automated analysis was performed by investigators blind to the experimental treatment. For identification of hits from our primary screen, statistical significance was determined by one-way ANOVA, with Dunnett's multiple comparisons test performed on treatments within individual experiments (from single clutches) compared to 1% DMSO controls. All other statistical analysis was performed using one-way or two-way ANOVA with Dunnett's or Tukey's multiple comparisons test where applicable or by two-tailed Student's t-test as stated in the text. See [Supplementary file 3](#supp3){ref-type="supplementary-material"} for details of raw data and tests per individual experiments and their relevant figure panel.
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10.7554/eLife.35136.025

###### Spreadsheet documenting the effect of all screened compounds, with their putative targets, on myelinating oligodendrocyte number, arranged by effect size.

Mean cell number effect size is normalized to DMSO-treated sibling controls, per screening session. Dunnett's multiple comparison test was used to assess statistical significance, with multiple comparison adjusted P value presented.

10.7554/eLife.35136.026

###### Detailed spreadsheet documenting the effect of all screened compounds, with their putative targets, and raw data of compound effect on myelinating oligodendrocyte number, n numbers per compound screened, standard deviations and statistical analyses.

As per [Supplementary file 1](#supp1){ref-type="supplementary-material"}, mean cell number effect size is normalized to DMSO-treated sibling controls, per screening session. Dunnett's multiple comparison test was used to assess statistical significance, with multiple comparison adjusted P value presented.

10.7554/eLife.35136.027

###### Overview of statistical tests carried out as per corresponding figure panel.

10.7554/eLife.35136.028

###### Overview of statistical significance for Dunnett's multiple comparison test with P values adjusted for multiple comparisons when data from [Supplementary file 1](#supp1){ref-type="supplementary-material"} is analysed with all samples, the first 6 or 3 samples from each treatment.

Results are only shown for treatments where at least one test was found to be significant. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001 and ns = not significant (p\>=0.05).

10.7554/eLife.35136.029
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All data generated or analysed during this study are included in the manuscript and supporting files.
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Decision letter
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University of Sheffield
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"An automated high-resolution in vivo screen to identify chemical regulators of myelination\" for consideration by *eLife*. Your article has been reviewed by three reviewers, and the evaluation has been overseen by Tanya Whitfield as the Reviewing Editor and Didier Stainier as the Senior Editor, The following individual involved in review of your submission has agreed to reveal their identity: Jason Rihel (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. In the discussion among the editors and reviewers, we feel your contribution would be appropriate to consider in the category of a Tools and Resources paper. The standards for such a contribution are just as high as for a Research Article, but the criteria for acceptance hinge on the technical excellence and utility of the work and a bit less on the mechanistic insight generated by the paper.

Summary:

Early et al., describe the development of an automated screening pipeline to identify chemical regulators of myelination in zebrafish. They have used mbp:GFP transgenic zebrafish lines to mark the myelinating glial cells and the VAST embryo liquid handler to orientate each fish precisely so that images of the CNS can be processed and quantified in an identical way. Using this platform, they have screened a library of 175 epigenetic targeted compounds and assayed for an increase in myelinating oligodendrocyte number. Five hit compounds were found, one of which they indicate is able to increase myelination in vivo.

Essential revisions:

As you will see, while reviewers 1 and 3 are largely positive, reviewer 2 has more substantial concerns. After discussion between the reviewers, it was agreed that some of these should be addressed. Essential revisions are:

1\) Please address the concerns from reviewer 2 over reproducibility, false positives and false negatives. Comparison with previously validated compounds will be important here.

2\) Please provide more information about the use of positive controls and show clearly that a positive control compound acts as expected in the screen.

3\) If a suitable mutant line is available, please address the suggestion from reviewer 1 to test the ability of hit compounds to rescue myelination in a fish with reduced myelination.

4\) Please provide more information about the structures of the hit compounds, as suggested by reviewer 1.

5\) Some further validation of the compounds is required, to give more insight into action of the compounds and their effects on oligodendrocyte biology. The reviewers have made several suggestions. After discussion, it was agreed that validation in a mammalian system would be beyond the scope of this manuscript, and so this is not essential. However, further validation in the zebrafish model is required.

Reviewer \#1:

The strength of this paper is in the detailed description of the assay and the automated image analysis. The data is of a high quality with clear and beautifully presented figures. The method they describe is novel and timely and will be of great interest to other researchers in the field. Orientating zebrafish larvae for high through-put image analysis has always been challenging, making power scores difficult to determine; using the VAST and image processing method described here will enable more robust screening assays to be undertaken in vivo. The down side to this is the time taken to screen a 96 well plate of fish and the number of compounds that can be screened lowers the through-put.

The automated pipeline for ROI determination and subsequent image analysis works well and is comparable to manual determination. This should be adaptable to many other projects. This screen identified five compounds that increased oligodendrocyte number. However, as HDACs are already known to increase oligodendrocyte number, the fact the library screened identified HAT inhibitors was not surprising, but, this provides a good validation of this approach.

The further characterisation of the compounds was limited and did not include an analysis of a dose response for all five compounds, and only a limited dose range for their hit compound splitomicin was tested. They did analyse if myelin levels increased with splitomicin too and found they could detect this using their automated analysis, however it would have been interesting to see if this compound could also rescue myelin in a myelin deficient fish.

Reviewer \#2:

This manuscript details work setting up a high-throughput in vivo screen of oligodendrocyte formation in the zebrafish embryo and testing this screening pipeline using a library of 175 compounds targeting enzymes involved in epigenetic and post-translational modifications. By using an in vivo system, the authors can assess toxicity or other global effects of compounds that would preclude their utility in drug development.

Any successful screening pipeline should several major features: a) High-throughput capacity b) Reproducibility c) Limit false positives and false negatives

The authors have successfully established a high-throughput method for assessing the formation of oligodendrocytes in zebrafish embryos. By automating the majority of the process, they are able to expedite data acquisition and analysis and eliminate human bias. Importantly, their automated processing is comparable to their manual processing (Figure 3D, Figure 4C).

However, this screening pipeline has serious shortcomings in features b (reproducibility) and c (limiting false positives and negatives). Furthermore, the lack of follow-up on the hits in this screen results in a manuscript that does not provide substantially new information on oligodendrocyte biology.

1\) Reproducibility. Within the screen itself (looking at Figure 2---figure supplement 2), 3 of the 5 hits that increase oligodendrocyte formation do not replicate this increase. The other 2 compounds are not tested more than once within the screen. For example, in experiment 1, the authors test SKP2-C25 (n=12; 1.31 fold increase, p = 0.0404). When the authors test this compound again in experiment 2, there is no increase in oligodendrocyte formation (1.08 fold increase, p=0.9634) with n=22 and a lower standard deviation for both the control and the SKP2-C25 condition than in experiment 1, indicating that this lack of statistical difference in experiment 2 is not due experiment 2 being underpowered as compared to experiment 1. NU9056 does not replicate the statistically significant increase from experiment 3 in experiment 9, and also does not replicate using the same methods in Figure 5C. C646 does replicate the statistical significant finding in experiment 1 in experiments 9 and 10.

This lack of reproducibility within the screen casts doubt on the ability of the pipeline to draw correct conclusions with high levels of confidence based on any one experiment -- substantially limiting the value of this screening pipeline.

It is important to highlight this data outside of the supplemental tables, so that readers can take this information into consideration when evaluating this system.

2\) False positives and false negatives. Since at least 3 compounds were found to both significantly increase and not change oligodendrocyte formation, this pipeline has returned either false positives or false negatives -- both of which should be minimized in a screen.

Is the screening platform able to detect real hits consistently? The authors should test previously validated compounds that increase oligodendrocyte formation in this screening platform to verify that these compounds show a consistent increase in oligodendrocyte formation.

Are these hits false positives? The authors should provide further validation of these hits -- particularly those that both increased and had no effect on oligodendrocyte formation depending on the experiment -- outside of this screening platform. Since the goal is to translate these compounds to treat human diseases, assessing the effects in a mammalian system would be a highly relevant way to further validate these hits.

3\) Why do various compounds targeting common molecules in similar manners (i.e. inhibiting sirtuin 1 and 2) have profoundly different effects on oligodendrocyte formation in this screen?

4\) A distinct disadvantage to this screening protocol as compared to others that have been previously published (e.g. Deshmukh et al., 2013; Mei et al., 2014) is that there is no method for discerning how each compound is affecting oligodendrocyte formation (e.g. directly acting on OPCs to cause an increase in OPC differentiation). Different diseases disrupt different aspects of oligodendrocyte formation and elucidating on which aspect of oligodendrocyte formation a compound is acting is important for discovering compounds useful for distinct diseases. As it stands, this manuscript does not provide substantial insights into oligodendrocyte biology. How do the identified compounds alter oligodendrocyte lineage cell biology? Visualizing both OPCs and oligodendrocytes could be a method by which the authors could provide some additional information on the mechanism of action of a compound. Which cell type(s) do they act on?

Reviewer \#3:

Overall this is a well-presented manuscript with well-documented results. The major advance of this study is mainly in the technical and coding work to make the VAST Bioimager, the spinning disk, and the analysis pipeline smoothly talk to each other to automatically pull out segmented, high resolution images for automated cell counting. This is a highly useful set of code in the zebrafish screening world, as it allows for automated analysis of specific image features, even in transgenic lines that may label other cell types, allowing one to even find interesting regionalized effects, for example in sensitivities across the A-P axis. There are other technical papers on the screening capabilities of the VAST Bioimager and related imaging methodologies, but this paper does still feel like an addition to these.

By fishy standards, the throughput of the screening example of only a few hundred compounds is low - only 175 compounds at a single dose vs. typical zebrafish screens these days of 1000s or even 10K compounds, but this is reasonable proof of principle for this kind of high-resolution imaging screen. The example of myelination is a well-chosen one to show off the capabilities, as such a screen would otherwise be a challenge. What might have been nice is a John Henry vs. the locomotive kind of comparison - i.e. how quickly could automated counters do the same screen, and what kinds of screening throughputs might now be possible and over what timescales? This might have really made the power of this approach clear.

Another weakness is that the manuscript is quite light on the biology- the compound hits haven\'t provided a clear biological insight as yet, nor even a clear target for further study. But I understand that *eLife* publishes technical/methods/resource papers and this would be a good example of that.

I don\'t have any major specific concerns. The code is well documented and freely available, the screening data is thorough, and the pipeline is well described.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"An automated high-resolution in vivo screen in zebrafish to identify chemical regulators of myelination\" for further consideration at *eLife*. Your revised article has been favorably reviewed by Didier Stainier (Senior Editor), Tanya Whitfield (Reviewing Editor), and three reviewers.

As you will see, all three reviewers agree that the manuscript has been improved. However, there are some remaining comments from reviewers 1 and 2 that need to be addressed before acceptance. It should be possible to address these comments by simple edits to the manuscript, and so we hope that they will be quick and straightforward to complete. Please see the reviews below for details:

Reviewer \#1:

Early et al., have made substantial changes to the text and figures of their manuscript to address the comments from all the reviewers. These include new experiments to address the validity of the hits identified in the screen and reworking of the text. Overall these changes have improved the manuscript and clarified areas that raised concern. Although some of these revisions have also highlighted other issues about the reproducibility of the results, the text has been modified to make it suitable for a Tools and Resources publication and I agree this is a better fit for the manuscript. The detailed methodology and analysis presented here will be of interest to anyone attempting small molecule screens and I therefore think the manuscript is now suitable for publication. I thank the authors for the modifications they have made and for responding to each of my points, including the re-evaluation of the power number data. I have made a few specific comments on the authors responses below and included a few very minor changes to the text.

1\) The authors have used a dose response assay on their top four hits and validated three of the compounds. One of these hits NU9056 was no longer able to increase cell number, although it did still show a localized effect in a different assay. The authors attribute the variability seen between different experiments in part to the short window of action for the compounds thus highlights the importance of having good controls and finding optimum doses and this is now discussed in the text. I think one of the issues here is that the control compound is still being validated and isn\'t optimal in all experiments and therefore is effectively an extra hit compound. The authors do discuss this issue in their response. I also wonder if the variability seen is linked to the order of the compounds when being imaged and the time taken. The authors have discussed varying the order of the compounds imaged on the VAST in response to a point made previously and it would be of interest to know if there is any correlation.

2\) To further characterize the action of the hit compounds the authors have used live imaging to show the control compound has increased proliferation. As this is quite a generic effect, it would be worth to note if this is specific to the OPCs or if there was an increase in all olig2:GFP and sox10:mRFP cells.

One of the hits, Splitomicin was also shown to increase MBP positive cells in rat oligodendrocyte cultures, further validating this hit compound in a different species and a different experimental assay as requested by one of the reviewers and this has improved the manuscript.

As there are just three strong hits it would be of interest to know if these two different approaches (live imaging, rat oligodendrocytes) had been tested with the other compounds (and control). While I think that having the data for one compound validates the approach and is fine for this manuscript, it might be worth mentioning if these experiments with the other compounds are planned or if they were inconclusive.

Reviewer \#2:

The authors have addressed most of the previous comments, however, there are a few remaining points to be addressed:

1\) Numerous times throughout the text, the authors state that SKP2-C25 and splitomicin promote OL lineage progression into OLs through increasing OPC proliferation (new data). Could the authors please elaborate on their suggestion that promoting OPC proliferation (where there are minimal asymmetric cell divisions that generate OLs (Hughes et al., 2013) could cause an increase in OL numbers? Known pro-proliferative compounds such as PDGF-AA are well-documented to decrease OL formation in vitro. In any case, proliferation does not necessarily promote lineage progression.

2\) In response to reviewer comments, the authors have increased the clarity of their data by including a discussion of the inconsistent reproducibility and false positives/negatives within the screen. This is important data - especially when considering the novel screening platform. In the spirit of transparency, the authors should report false negatives in the Results section. It is appropriate to report the non-significant trials of C646 and NU9056 when reporting their significant trials in detail (subsection "Chemical screen for compounds that regulate myelinating oligodendrocyte number", C646; NU9056). The non-significant trial of SKP2-C25 could be reported here or elsewhere in the Results section.

3\) Data from Figure 6 does not seem to be in Supplementary file 3. Additionally, please comment in the text or legend on how this data was obtained. Was it using the fully automated screening platform or another method?

Reviewer \#3:

This resubmission has substantial new data, including evidence that the candidate molecules found in the fish screen also work on mammalian cells in vitro. They have rewritten the manuscript to highlight more clearly the automation methods and detail several screening issues that can be addressed in various ways.

The new submission has addressed all of my concerns.

10.7554/eLife.35136.032

Author response

> The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. In the discussion among the editors and reviewers, we feel your contribution would be appropriate to consider in the category of a Tools and Resources paper. The standards for such a contribution are just as high as for a Research Article, but the criteria for acceptance hinge on the technical excellence and utility of the work and a bit less on the mechanistic insight generated by the paper.

We are very grateful for the opportunity to submit a revised version of our manuscript. We agree that the manuscript would be well suited to the Tools and Resources category and resubmit it accordingly. We have added a significant amount of new data and data analysis to our manuscript to address feedback and have reoriented much of our Discussion section to fit better with the Tools and Resources format.

The main experimental and data analysis additions are:

In-depth characterisation of the effects of SKP2-C25 on the oligodendrocyte lineage. As we clarify in the manuscript, this compound was the positive control that we used in our screen. We now provide dose response information on the compound effect on oligodendrocyte number (new Figure 4). We also provide time-lapse imaging based data showing that this compound promotes OPC proliferation in the developing zebrafish (new Figure 4---figure supplement 1 and Video 6).

We also provide dose response studies for the four additional compounds that increase oligodendrocyte number, which addresses many of the points brought up regarding reproducibility. These data are now presented in a new Figure 6.

Also relating to the issue of screen refinement and reproducibility, we have carried out a post hoc analysis of our screen to test how effective different "n" numbers would have been in identifying validated hits. This analysis is now presented as a Supplementary file 4.

We also show data that indicate that our top hit compound, splitomicin, increases myelinating oligodendrocyte number in rat oligodendrocyte cultures, validating conservation of effect across species.

We believe that these additions greatly strengthen our manuscript and are grateful to the reviewers for helping us produce a better paper.

> \[...\] Essential revisions:
>
> As you will see, while reviewers 1 and 3 are largely positive, reviewer 2 has more substantial concerns. After discussion between the reviewers, it was agreed that some of these should be addressed. Essential revisions are:
>
> 1\) Please address the concerns from reviewer 2 over reproducibility, false positives and false negatives. Comparison with previously validated compounds will be important here.

We have addressed these important points in detail in our revision, by the inclusion of a significant amount of new data, data analysis and discussion.

Point by point revisions are outlined throughout the original reviews.

The principal new data of relevance to the issues of reproducibility, false positives and negatives are concentration series tests of hit compounds. We show that 3 of the 4 hit compounds identified as increasing oligodendrocyte number were validated through concentration series analyses. However, all compounds exerted their functions over relatively narrow concentration ranges, which likely contributes to the variability seen in the screen. These data are now presented in a new Figure 6.

One of our hit compounds did not show activity in increasing oligodendrocyte number in this concentration series analysis but did exhibit a region-specific effect in increasing oligodendrocyte number in an independent experiment (Figure 7). Therefore, this is not considered a fully validated hit, and would not be pursued further.

To further test how robust our screen was in identifying the validated hits, we carried out a new post hoc analysis to test how many hit compounds would have been identified with differing "n" values. We found that the n number we selected was indeed the most robust, given that a significant number of false positives and negatives were apparent in taking lower "n" numbers. These data are now presented in a new Supplementary file 4.

We also now discuss in much greater detail the issue of false positives and negatives in screening and outline important refinements that should be considered for future quantitative screens.

> 2\) Please provide more information about the use of positive controls and show clearly that a positive control compound acts as expected in the screen.

We now clarify that the compound SKP2-C25 was used as the positive control in designing our screen, and that it acted as expected in our screen. We also discuss the fact that this compound occasionally exhibited variable effects, due to a narrow effective concentration range (shown in new Figure 4) as well as solubility issues and was therefore not an optimal control. However, we did not have an alternative positive control for our assay prior to initiating our screen. We have now identified compounds that more robustly increase oligodendrocyte number and we discuss the need for robust positive controls in executing quantitative screens and for applying rigorous criteria for defining hits and powering screens accordingly.

> 3\) If a suitable mutant line is available, please address the suggestion from reviewer 1 to test the ability of hit compounds to rescue myelination in a fish with reduced myelination.

Given the prospective targets of the compounds identified in our screen, there is not a suitable mutant phenotype to try to rescue with these compounds. However, instead, to strengthen our manuscript and further validate the ability of our assay to identify compounds of relevance to myelination, we added an experiment which tested how our hit compound splitomicin affected mammalian oligodendrocyte lineage progression. These new experiments showed that splitomicin also increased myelinating oligodendrocyte number in rat in vitro cultures and did so by promoting oligodendrocyte progenitor cell proliferation. These data are now shown in a new Figure 9.

> 4\) Please provide more information about the structures of the hit compounds, as suggested by reviewer 1.

We have added this information as requested, as part of a new figure in which we carry out assessments of how hit compounds affect myelinating oligodendrocyte number across a range of concentrations. These data are shown in new Figure 4 and Figure 6.

> 5\) Some further validation of the compounds is required, to give more insight into action of the compounds and their effects on oligodendrocyte biology. The reviewers have made several suggestions. After discussion, it was agreed that validation in a mammalian system would be beyond the scope of this manuscript, and so this is not essential. However, further validation in the zebrafish model is required.

In addition, we also found that splitomicin increased rat oligodendrogenesis in vitro (new Figure 9).

> Reviewer \#1:
>
> \[...\] The automated pipeline for ROI determination and subsequent image analysis works well and is comparable to manual determination. This should be adaptable to many other projects. This screen identified five compounds that increased oligodendrocyte number. However, as HDACs are already known to increase oligodendrocyte number, the fact the library screened identified HAT inhibitors was not surprising, but, this provides a good validation of this approach.
>
> The further characterisation of the compounds was limited and did not include an analysis of a dose response for all five compounds, and only a limited dose range for their hit compound splitomicin was tested. They did analyse if myelin levels increased with splitomicin too and found they could detect this using their automated analysis, however it would have been interesting to see if this compound could also rescue myelin in a myelin deficient fish.

We thank the reviewer for their feedback, and now provide dose response data for all five compounds that increase myelinating oligodendrocyte number. These data are now shown in new Figure 4 and Figure 6. Given what is known about the prospective targets of our hit compounds, a suitable mutant was not available to test for possible rescue. However, to further characterize the effects of our compounds, we now include time-lapse imaging data showing how treatment with SKP2-C25, promotes OPC proliferation in vivo. These data are shown in a new Figure 4---figure supplement 1 and Video 6. In addition, we tested how splitomicin affected development of rat oligodendrocytes in vitro, validating our findings in zebrafish. These data are now shown in a new Figure 9.

> Reviewer \#2:
>
> \[...\] 1) Reproducibility. Within the screen itself (looking at Figure 2---figure supplements 2), 3 of the 5 hits that increase oligodendrocyte formation do not replicate this increase. The other 2 compounds are not tested more than once within the screen. For example, in experiment 1, the authors test SKP2-C25 (n=12; 1.31 fold increase, p = 0.0404). When the authors test this compound again in experiment 2, there is no increase in oligodendrocyte formation (1.08 fold increase, p=0.9634) with n=22 and a lower standard deviation for both the control and the SKP2-C25 condition than in experiment 1, indicating that this lack of statistical difference in experiment 2 is not due experiment 2 being underpowered as compared to experiment 1. NU9056 does not replicate the statistically significant increase from experiment 3 in experiment 9, and also does not replicate using the same methods in Figure 5C. C646 does replicate the statistical significant finding in experiment 1 in experiments 9 and 10.
>
> This lack of reproducibility within the screen casts doubt on the ability of the pipeline to draw correct conclusions with high levels of confidence based on any one experiment -- substantially limiting the value of this screening pipeline.
>
> It is important to highlight this data outside of the supplemental tables, so that readers can take this information into consideration when evaluating this system.
>
> 2\) False positives and false negatives. Since at least 3 compounds were found to both significantly increase and not change oligodendrocyte formation, this pipeline has returned either false positives or false negatives -- both of which should be minimized in a screen.
>
> Is the screening platform able to detect real hits consistently? The authors should test previously validated compounds that increase oligodendrocyte formation in this screening platform to verify that these compounds show a consistent increase in oligodendrocyte formation.
>
> Are these hits false positives? The authors should provide further validation of these hits -- particularly those that both increased and had no effect on oligodendrocyte formation depending on the experiment -- outside of this screening platform. Since the goal is to translate these compounds to treat human diseases, assessing the effects in a mammalian system would be a highly relevant way to further validate these hits.

We thank the reviewer for highlighting their concerns around reproducibility, false positives and false negatives in our screen. We entirely agree with the reviewer that we should have addressed these points in detail in our original manuscript. We now add substantive new data that validates 4/5 compounds that increase oligodendrocyte number, and which do indeed identify one compound as a marginal hit that would not warrant further investigation.

We provide dose response data on all five compounds that increase oligodendrocyte number and find that 4 of these compounds exhibit phenotypes in these studies, albeit over a relatively narrow concentration window (see new Figure 4 and Figure 6). Indeed, we speculate that the variability that the reviewer pointed out in the screen, particularly with respect to SKP2-C25 is likely to reflect both this limited range of efficacy and the fact that we do not assess actual compound concentration prior to a screen. For example, SKP2-C25 was provided at 10mM, but we have subsequently found it to be poorly soluble at this concentration. Therefore, we discuss the limitations of executing a screen at a single compound concentration.

Our dose response tests did, however, cast doubt on the validation of NU9056 as a hit (new Figure 6), whereby it did not show efficacy in dose response tests at any concentration, but did show a region specific effect in an independent test following the screen (Figure 7). Therefore, we classify this as a non-validated hit, which would not be pursued further, and in effect does represent a false positive.

We now also include a post hoc analysis of our screen that tests the premise that a predicted n=9 would have had the capacity to detect subtle changes in oligodendrocyte number. We find that lowering this n to either 6 or 3 would have led to identification of both false positive hits, and, more concerningly precluded identification of validated hits, thus returning false negatives (Supplementary file 4). We also discuss the issues of reproducibility and screen throughput in our new Discussion section.

We also provide further characterization of the effects of SKP2-C25, including time-lapse imaging based analyses, which demonstrate that the compound increases OPC proliferation in the zebrafish spinal cord (new Figure 4 and Figure 4---figure supplement 1 and Video 6).

As suggested by the reviewer, we have tested our top hit in a mammalian context, using a rat in vitro culture system, and show that splitomicin treatment increases myelinating oligodendrocyte number (new Figure 9).

Therefore, our screen identified compounds with validated effects on the oligodendrocyte lineage, including across species.

> 3\) Why do various compounds targeting common molecules in similar manners (i.e. inhibiting sirtuin 1 and 2) have profoundly different effects on oligodendrocyte formation in this screen?

We discuss the fact that further studies are required to deconvolve the target(s) through which the various compounds identified in our screen function. For example, it is possible that splitomicin mediates its effects on either sirtuin 1 or sirtuin 2, or potentially through a balance of both. Different compounds that hit similar targets, may do so with different affinities for one or other of the shared targets. Indeed, it is also possible that the effective compounds mediate their functions on additional unknown targets.

> 4\) A distinct disadvantage to this screening protocol as compared to others that have been previously published (e.g. Deshmukh et al., 2013; Mei et al., 2014) is that there is no method for discerning how each compound is affecting oligodendrocyte formation (e.g. directly acting on OPCs to cause an increase in OPC differentiation). Different diseases disrupt different aspects of oligodendrocyte formation and elucidating on which aspect of oligodendrocyte formation a compound is acting is important for discovering compounds useful for distinct diseases. As it stands, this manuscript does not provide substantial insights into oligodendrocyte biology. How do the identified compounds alter oligodendrocyte lineage cell biology? Visualizing both OPCs and oligodendrocytes could be a method by which the authors could provide some additional information on the mechanism of action of a compound. Which cell type(s) do they act on?

This is an important point, particularly with respect to triaging compounds for effects on different aspects of oligodendrocyte lineage development. We show here that both SKP2-C25 (new Figure 4---figure supplement 1 and Video 6) and splitomicin (new Figure 9) promote oligodendrocyte proliferation. We also discuss how combining further complementary studies in both zebrafish and cellular platforms will continue to provide important information on the cellular mechanisms of compound function.

> Reviewer \#3:
>
> \[...\] By fishy standards, the throughput of the screening example of only a few hundred compounds is low- only 175 compounds at a single dose vs. typical zebrafish screens these days of 1000s or even 10K compounds, but this is reasonable proof of principle for this kind of high-resolution imaging screen. The example of myelination is a well-chosen one to show off the capabilities, as such a screen would otherwise be a challenge. What might have been nice is a John Henry vs. the locomotive kind of comparison- i.e. how quickly could automated counters do the same screen, and what kinds of screening throughputs might now be possible and over what timescales? This might have really made the power of this approach clear.

We have now included a comparison of the speed of fully automated image analysis, versus a semi-automated approach wherein one manually corrects any errors in identification of cells versus a fully manual quantitation of cell number in 3D data stacks. This is now included in subsection "Automated quantification of oligodendrocyte cell number". In addition, we have included more extensive discussion on how to best scale up screen throughput using this system in our new Discussion section.

> Another weakness is that the manuscript is quite light on the biology- the compound hits haven\'t provided a clear biological insight as yet, nor even a clear target for further study. But I understand that eLife publishes technical/methods/resource papers and this would be a good example of that.

We have now added data showing that SKP2-C25 increases the proliferation of oligodendrocyte progenitor cells (OPCs) in zebrafish (new Figure 4---figure supplement 1 and Video 6) and that splitomicin promotes oligodendrocyte progression by increasing the proliferation of mammalian OPCs in culture (new Figure 9).

We thank the reviewer for their suggestion to re-submit our manuscript in the Tools and Resources category and agree that this is more appropriate.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Reviewer \#1:
>
> \[...\] 1) The authors have used a dose response assay on their top four hits and validated three of the compounds. One of these hits NU9056 was no longer able to increase cell number, although it did still show a localized effect in a different assay. The authors attribute the variability seen between different experiments in part to the short window of action for the compounds thus highlights the importance of having good controls and finding optimum doses and this is now discussed in the text. I think one of the issues here is that the control compound is still being validated and isn\'t optimal in all experiments and therefore is effectively an extra hit compound. The authors do discuss this issue in their response. I also wonder if the variability seen is linked to the order of the compounds when being imaged and the time taken. The authors have discussed varying the order of the compounds imaged on the VAST in response to a point made previously and it would be of interest to know if there is any correlation.

The reviewer is correct in suggesting that the length of each treatment run is important, as one will certainly see larger variability in longer screening run, given continuous development of the animal. Indeed, the length of screening run in which our positive control compound represented a false negative was two times longer (8 hours) than when it was identified correctly as a hit (4 hours). This is a very astute point by the reviewer and we now refer to this in both the Results section and Discussion section.

> 2\) To further characterize the action of the hit compounds the authors have used live imaging to show the control compound has increased proliferation. As this is quite a generic effect, it would be worth to note if this is specific to the OPCs or if there was an increase in all olig2:GFP and sox10:mRFP cells.

The density of olig2:GFP cells makes their precise quantitation from the data to hand very difficult. We do not see any general effects on animal size suggestive of general effects on proliferation but cannot exclude the possibility that compounds may exhibit effects on other cell types. We now note this in our Discussion section and underline the need to carry out cell-type specific genetic analysis of targets function (subsection "Novel regulators of oligodendrocyte formation").

> One of the hits, Splitomicin was also shown to increase MBP positive cells in rat oligodendrocyte cultures, further validating this hit compound in a different species and a different experimental assay as requested by one of the reviewers and this has improved the manuscript.
>
> As there are just three strong hits it would be of interest to know if these two different approaches (live imaging, rat oligodendrocytes) had been tested with the other compounds (and control). While I think that having the data for one compound validates the approach and is fine for this manuscript, it might be worth mentioning if these experiments with the other compounds are planned or if they were inconclusive.

We have only carried out the analyses on the respective compounds as shown to date, and we further underscore in the text the need to explore deeper analysis of all compounds in the future.

> Reviewer \#2:
>
> The authors have addressed most of the previous comments, however, there are a few remaining points to be addressed:

*1) Numerous times throughout the text, the authors state that SKP2-C25 and splitomicin promote OL lineage progression into OLs through increasing OPC proliferation (new data). Could the authors please elaborate on their suggestion that promoting OPC proliferation (where there are minimal asymmetric cell divisions that generate OLs (Hughes et al., 2013) could cause an increase in OL numbers? Known pro-proliferative compounds such as PDGF-AA are well-documented to decrease OL formation* in vitro*. In any case, proliferation does not necessarily promote lineage progression.*

We agree with the reviewer that promoting oligodendrocyte proliferation does not necessarily promote lineage progression. We clarify further in the text, why increasing OPC proliferation can lead to an increase in myelinating oligodendrocyte number. In subsection" Validation of automated analysis to identify changes in myelinating oligodendrocyte 216 number" we explain "We have previously shown that oligodendrocytes differentiate by default in zebrafish to mediate the early myelination observed in the larval spinal cord (Almeida et al., 2018). Therefore, upon an increase of OPC proliferation following SKP2-C25 treatment, there is a larger pool of OPCs that differentiate by default, leading to the observed increase in myelinating oligodendrocytes."

In subsection "Automated analysis of myelination", regarding the mammalian in vitro data, we note that "We saw an increase in the number of Ki67-expressing, olig2-expressing cells, upon splitomicin treatment (Figure 9), indicating that the observed increase in myelinating oligodendrocyte number was due to increased proliferation and subsequent differentiation of a larger pool of OPCs."

We have revised the text to ensure that we do not suggest anywhere that an increase in OPC proliferation promotes oligodendrocyte lineage progression and thank the reviewer for this point.

> 2\) In response to reviewer comments, the authors have increased the clarity of their data by including a discussion of the inconsistent reproducibility and false positives/negatives within the screen. This is important data-especially when considering the novel screening platform. In the spirit of transparency, the authors should report false negatives in the Results section. It is appropriate to report the non-significant trials of C646 and NU9056 when reporting their significant trials in detail (subsection "Chemical screen for compounds that regulate myelinating oligodendrocyte number", C646; NU9056). The non-significant trial of SKP2-C25 could be reported here or elsewhere in the Results section.

We now include reference to the fact that SKP2-C25 failed to reach significance in one of its two screening runs in the Results section and note that the duration of the screening run was longer the time that it was not identified as a hit, likely due to the increased variability associated with longer screening runs on live animals.

> 3\) Data from Figure 6 does not seem to be in Supplementary file 3. Additionally, please comment in the text or legend on how this data was obtained. Was it using the fully automated screening platform or another method?

We thank the reviewer for spotting this omission and we now include the new data accordingly and clarify in the Results section that this was indeed acquired on the automated screening platform.

[^1]: These authors contributed equally to this work.
